Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well. To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments: Target Disease Indication Breast Cancer Chronic Lymphocytic Leukemia Colorectal Cancer Head and Neck Cancer Lung Cancer Lupus Nephritis Melanoma Multiple Myeloma Primary Sjögren's Syndrome Others Target Immune Checkpoint B7-H3 CD38 CD40 CD47 Others Mechanism of Action Inhibitory Stimulatory Therapeutic Modality Monoclonal Antibody Small Molecule Type of Therapy Monotherapy Combination Therapy Route of Administration Intravenous Subcutaneous Others Key Geographical Regions North America Europe Asia-Pacific and the Rest of the World The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain: Bristol Myers Squibb GlaxoSmithKline Incyte Novartis Trillium Therapeutics Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape: Clinical and Preclinical Molecules 5. Market Landscape: Therapies Targeting Cd47 6. Market Landscape: Therapies Targeting 4-1bb 7. Clinical Trial Analysis 8. Company Profiles: Next Generation Inhibitors and Stimulators 9. Academic Grants Analysis 10. Partnerships and Collaborations 11. Target Competitiveness Analysis 12. Big Pharma Initiatives 13. Market Forecast and Opportunity Analysis 14. Concluding Remarks 15. Executive Insights 16. Appendix 1: Tabulated Data 17. Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
